We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Bioepis

News List

Samsung Biologics Acquires Full Ownership of Samsung Bioepis contractpharma
January 29, 2022
Buys out Biogen’s stake in the joint venture for $2.3 billion.
Samsung Bioepis, 3SBio partner to expand biosimilar business in China biospectrumasia
January 07, 2019
Samsung Bioepis Co., Ltd. has announced that its rapidly growing biosimilar business will expand into mainland China through a licensing agreement with 3SBio Inc.
Samsung and Bioepis launch third Humira biosimilar in Europe pharmafile
October 19, 2018
Hot on the heels of Amgen, Samsung Bioepis and Biogen have announced the launch of their own biosimilar version of Abbvie’s best-selling drug Humira (adalimumab) in Europe.
Biogen, Bioepis resolve dispute over Humira biosimilar biospectrumasia
April 08, 2018
AbbVie will grant patent licenses for the biosimilar, branded as IMRALDI, in Europe on a country-specific basis.
Samsung Bioepis joins hands with Takeda for biotech drugs biospectrumasia
August 22, 2017
The partnership will develop novel biologic drugs in "unmet disease areas".